99% Savings - Buy Just @1 Rs X
Voglital M 0.3 Tablet SR, a prescription drug, is manufactured in various forms such as Tablet. Voglital M 0.3 Tablet SR also has some secondary and off-label uses. These are listed below.
The optimal dosage of Voglital M 0.3 Tablet SR is largely dependent on the individual's body weight, medical history, gender and age. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Refer to the dosage section for a detailed discussion.
Common side effects of Voglital M 0.3 Tablet SR include Weakness, Headache, Nausea or vomiting. Besides the aforementioned side effects, there are other adverse effects of Voglital M 0.3 Tablet SR as well, which are listed below. These side effects of Voglital M 0.3 Tablet SR are usually temporary and subside with the completion of treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
It is also important to note that Voglital M 0.3 Tablet SR has a Severe effect for pregnant women and Severe effect on lactating mothers. Warnings related to Voglital M 0.3 Tablet SR's effects on the liver, heart and kidney, if any, have been listed below.
Voglital M 0.3 Tablet SR is contraindicated in people with pre-existing medical conditions like Diabetic Ketoacidosis as it can result in adverse effects.
Drug interactions for Voglital M 0.3 Tablet SR have been reported in the medical literature. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Voglital M 0.3 Tablet SR is considered not safe while driving, and is not addictive.
Voglital M 0.3 Tablet SR is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
Adult |
|
Geriatric |
|
Is the use of Voglital M 0.3 Tablet SR safe for pregnant women?
Pregnant women may get severe side effects after taking Voglital M. If you are pregnant, do not take Voglital M without a doctor's advice.
Is the use of Voglital M 0.3 Tablet SR safe during breastfeeding?
Women who are breastfeeding, may experience serious side effects after taking Voglital M. So it is adviced to consult the doctor before using it.
What is the effect of Voglital M 0.3 Tablet SR on the Kidneys?
Kidney can be affected by Voglital M. If you experience any unwanted effects of this drug, stop taking it. You should take it again only after medical advice.
What is the effect of Voglital M 0.3 Tablet SR on the Liver?
You may experience side effects on your liver after taking Voglital M. If this happens, then discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Voglital M 0.3 Tablet SR on the Heart?
Voglital M has very mild side effects on the heart.
If you are suffering from any of the following diseases, you should not take Voglital M 0.3 Tablet SR unless your doctor advises you to do so -
Is this Voglital M 0.3 Tablet SR habit forming or addictive?
No, you will not get addicted to Voglital M 0.3 Tablet SR.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Voglital M 0.3 Tablet SR. So it is best to avoid driving.
Is it safe?
Voglital M 0.3 Tablet SR is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, Voglital M 0.3 Tablet SR cannot treat any kind of mental disorder.
Interaction between Food and Voglital M 0.3 Tablet SR
Due to a lack of research, nothing can be said about the consequences of taking Voglital M 0.3 Tablet SR together with food.
Interaction between Alcohol and Voglital M 0.3 Tablet SR
Information about the interaction of Voglital M 0.3 Tablet SR and alcohol is not currently available because this topic has not been researched yet.
Voglital M is the brand name for voglibose. It is an oral antidiabetic drug that belongs to the class of medicine called alpha-glucosidase inhibitor. It is used in single or combined with other drugs to treat diabetes.
Yes, Voglital M can cause low blood sugar (hypoglycemia). However, this can also occur if you delay or miss a meal, drink alcohol, exercise more than usual, can't eat due to stomach upset, and taking other antidiabetic medicine with voglibose. So, regular monitoring of blood glucose level is needed and be cautious of symptoms of hypoglycemia. It is best to consult your doctor if you feel any unwanted effects.
Yes, Voglital M can cause night sweat, the exact mechanism of sweating is not known. But some research suggests that it causes hypoglycemia (low blood sugar) especially at night which leads to night sweats. You need to monitor your blood glucose level regularly and talk to your doctor as your dose may need to be adjusted.
Voglital M contain voglibose. It works by inhibiting the enzyme (alpha-glucosidase) that reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. Hence in this way, Voglital M reduces blood sugar levels.
Take Voglital M as advised by your doctor. It can be taken orally three times daily immediately before each meal. Precautions must be taken in patients with improper liver or kidney function.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 277
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826